Mereo BioPharma (MREO) Free Cash Flow (2023 - 2026)

Mereo BioPharma (MREO) has reported Free Cash Flow for 4 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow rose 48.35% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.0 million (up 18.79% YoY) and the FY2025 annual result came in at -$31.0 million, up 5.61% from the prior year.
• Free Cash Flow grew to -$4.3 million in Q1 2026 per MREO's latest filing, from -$7.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for MREO reached as high as $2.7 million in Q3 2023 and fell as low as -$9.4 million in Q4 2024.
• A 4-year average of -$6.8 million and a median of -$7.7 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 382.78% — and 2026, when it soared 48.35%.
• Year by year, Free Cash Flow stood at -$6.8 million in 2023, then sank by 38.75% to -$9.4 million in 2024, then climbed by 18.45% to -$7.7 million in 2025, then jumped by 43.87% to -$4.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$4.3 million, -$7.7 million, and -$7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.